Study to Investigate the Treatment Benefit of Probiotic Lactobacillus Crispatus M247 in Women Undergoing Homologous Level 2 Assisted Reproductive Technology (ART) Procedures
NCT ID: NCT05871242
Last Updated: 2023-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
160 participants
INTERVENTIONAL
2020-01-10
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Oral Probiotic Blend on Pregnancy Outcome
NCT04009889
Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses
NCT06245486
Evaluate the Use of a New Probiotic Strain in Couples With Fertility Problems and Dysbiosis.
NCT03701893
Clinical Trial to Evaluate the Effect of an Oral Probiotic on the Vaginal Flora
NCT03923985
Effect of Consuming a Combination of Probiotic Strains on Postpartum Depression
NCT06651424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study the investigators aim to explore the hypothesis that recreating a favorable vaginotype through the intake of the probiotic Lactobacillus crispatus M247 can have a positive effect in achieving pregnancy in cryopreserved cycles as well as a positive relationship between vaginal, endometrial (still unknown), gut and oral microbiota.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment arm
Treatment with Lactobacillus crispatus M247
Probiotic Lactobacillus crispatus M247
Patient who have received probiotic Lactobacillus crispatus M247
Control arm
No Probiotic treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic Lactobacillus crispatus M247
Patient who have received probiotic Lactobacillus crispatus M247
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cryopreserved oocytes
* D3 embryos
* D5 blastulae
* Age 18-45
Exclusion Criteria
* Uterine malformations.
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Treviso Regional Hospital
NETWORK
Dr. Amjad Khan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Amjad Khan
Professor of Clinical Biochemistry and Experimental Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ART center, Hospital of Conegliano
Treviso, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LUMHS/REC/-253
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.